1. Home
  2. LMB vs ACRS Comparison

LMB vs ACRS Comparison

Compare LMB & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Limbach Holdings Inc.

LMB

Limbach Holdings Inc.

HOLD

Current Price

$46.29

Market Cap

917.0M

ML Signal

HOLD

Logo Aclaris Therapeutics Inc.

ACRS

Aclaris Therapeutics Inc.

HOLD

Current Price

$5.85

Market Cap

868.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMB
ACRS
Founded
1901
2012
Country
United States
United States
Employees
1400
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
917.0M
868.6M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
LMB
ACRS
Price
$46.29
$5.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$116.67
$10.20
AVG Volume (30 Days)
303.2K
1.8M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
25.68
69.01
EPS
0.76
N/A
Revenue
$646,804,000.00
$1,683,000.00
Revenue This Year
$15.96
N/A
Revenue Next Year
$5.90
$4.24
P/E Ratio
$64.08
N/A
Revenue Growth
24.68
N/A
52 Week Low
$47.15
$1.58
52 Week High
$128.57
$6.52

Technical Indicators

Market Signals
Indicator
LMB
ACRS
Relative Strength Index (RSI) 25.78 56.40
Support Level N/A $4.13
Resistance Level $85.28 $5.87
Average True Range (ATR) 4.16 0.38
MACD -2.81 0.03
Stochastic Oscillator 0.64 54.49

Price Performance

Historical Comparison
LMB
ACRS

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a building systems solutions firm that designs, delivers, and maintains mechanical (heating, ventilation, and air conditioning), electrical, plumbing, and controls (MEPC) systems. The Company partners with owners and operators of facilities across healthcare, industrial and manufacturing, data centers, life sciences, higher education, and cultural and entertainment markets. It operates through two segments: Owner Direct Relationships (ODR), which generates maximum revenue and includes owner direct projects, maintenance, and service on MEPC systems; and General Contractor Relationships (GCR), which manages new construction or renovation projects involving MEPC systems awarded by general contractors or construction managers.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Share on Social Networks: